Education
About Us
Working with TipRanks
Follow Us
Immunicum AB (DE:1YG0)
:1YG0
1YG0 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.41 - €0.89
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€32.85M
Enterprise Value€315.78M
Total Cash (Recent Filing)€84.73M
Total Debt (Recent Filing)kr20.29M
Price to Earnings (P/E)―
Beta-1.95
Next Earnings
Aug 21, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding52,084,580
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)0.59
Price to Sales (P/S)0.00
P/FCF Ratio-5.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.67Price Target Upside4.69% Upside
Rating ConsensusHold
Number of Analyst Covering0
1YG0 FAQ
What was Immunicum AB’s price range in the past 12 months?
Immunicum AB lowest stock price was €0.41 and its highest was €0.89 in the past 12 months.
What is Immunicum AB’s market cap?
Immunicum AB’s market cap is €32.85M.
When is Immunicum AB’s upcoming earnings report date?
Immunicum AB’s upcoming earnings report date is Aug 21, 2025 which is in 33 days.
How were Immunicum AB’s earnings last quarter?
Currently, no data Available
Is Immunicum AB overvalued?
According to Wall Street analysts Immunicum AB’s price is currently Undervalued.
Does Immunicum AB pay dividends?
Immunicum AB does not currently pay dividends.
What is Immunicum AB’s EPS estimate?
Immunicum AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immunicum AB have?
Immunicum AB has 52,084,580 shares outstanding.
What happened to Immunicum AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Immunicum AB?
Currently, no hedge funds are holding shares in DE:1YG0
Company Description
Immunicum AB
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I/II ALISON clinical trial for the treatment of ovarian cancers. It has a research collaboration with PCI Biotech Holding ASA for novel cancer vaccination treatment; and with Icahn School of Medicine at Mount Sinai. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Isofol Medical AB
―
Xintela AB
―
Intervacc AB
―
Guard Therapeutics International AB
―